Posts in tag

Guardant


To support the commercialization of the blood-based companion diagnostic (CDx) test Guardant360 CDx for AMG 510, Guardant Health, Inc, will collaborate with Amgen, developer of AMG 510, and pursue an FDA Pre-Market Approval as a CDx for AMG 510 in patients with metastatic non–small cell lung cancer (NSCLC) with a KRAS G12C mutation, according to a press …

What happened Shares of Guardant Health (NASDAQ:GH) jumped 12% on Friday following the company’s announcement of its third-quarter results after the market closed on Thursday. Guardant Health reported that its revenue skyrocketed 181% year over year in Q3 to $60.8 million. The company posted a net loss of $12.8 million, or $0.14 per share, a …